Article of Significant Interest Selected from This Issue by the Editors

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-12-01 DOI:10.1128/cvi.00278-17

引用次数: 0

Abstract

A Single High Dose of CVD 103-HgR Live Oral Cholera Vaccine Is More Immunogenic than a Standard Dose or than One or Two Doses of Shanchol Oral Killed Vaccine In a study by Sow et al. (e00265-17), Malian adults were randomly allocated to receive a single standard dose (108 CFU) or a high dose (109 CFU) of CVD 103-HgR live oral cholera vaccine or two doses (2 weeks apart) of Shanchol killed oral cholera vaccine. Inaba serum vibriocidal antibody responses (seroconversion rate, geometric mean titer [GMT], and fold rise) were compared. High-dose CVD 103-HgR exhibited significantly higher seroconversion rates than one or two doses of Shanchol and significantly higher GMTs than standard-dose CVD 103-HgR. A single high dose of CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess effectiveness and practicality in field situations.

查看原文本刊更多论文

由编辑从本期杂志中选出的具有重要意义的文章

在Sow等人(e00265-17)的一项研究中，马里成年人被随机分配接受单次标准剂量(108 CFU)或高剂量(109 CFU)的CVD 103-HgR口服霍乱活疫苗或两剂(间隔2周)的Shanchol口服霍乱灭活疫苗。比较稻叶血清杀弧菌抗体反应(血清转化率、几何平均滴度[GMT]和倍数上升)。高剂量CVD 103-HgR血清转化率显著高于单剂量或双剂量Shanchol, GMTs显著高于标准剂量CVD 103-HgR。建议在发展中国家加速评价单次高剂量CVD 103-HgR，以评估实地情况下的有效性和实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.